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Oral Presentations S191Conclusion: This medication use evaluation showed that a 48 hour
load of 0.03 mg/kg/day followed by a 0.02 mg/kg/day maintenance
dose of tacrolimus demonstrated potential to optimize tacrolimus
therapy. When compared to the control group, the study group ex-
hibited fewer patients with supratherapeutic levels with no difference
in the number of patients with levels\6 ng/mL.The dosing strategy
implemented at Emory Healthcare has resulted in a greater number
of patients with tacrolimus levels within the desired range.101
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In the pediatric population, altered busulfan pharmacokinetics
have been described in patients less than 4 years of age. Higher doses
of busulfan have been utilized to ensure therapeutic drug levels are
achieved. Patients less than 1 year of age are included in this higher
dosing strategy although the data in this population is minimal. The
purpose of this study was to characterize the dosing of patients less
than 1 year of age and compare the cumulative busulfan dose re-
ceived to that of patients between 1 and 4 years of age.
Methods: A retrospective review was performed and included six-
teen patients less than 4 years of age who received intravenous busul-
fan as part of a conditioning regimen prior to transplant. The
cumulative busulfan dose was calculated to assess the primary end-
point. Secondary endpoints included evaluation of toxicities and en-
graftment.
Results: Of the sixteen patients, ten patients were between 1 and 4
years of age and six patients were less than 1 year of age. The initial
busulfan dose was similar between groups with children less than 1
year of age receiving a mean of 0.93 mg/kg/dose (range 0.8-1 mg/
kg/dose) compared to 0.99 mg/kg/dose (range 0.8-1.28 mg/kg/
dose) in the 1-4 year group (p 5 0.4). Pharmacokinetic analysis
was performed in 15 patients (94%). Eight patients (80%) in the 1-
4 year group required an increased dose, while two patients (33%)
required a decrease in the less than 1 year group. The mean cumula-
tive busulfan dose was significantly higher in the 1-4 year group, 1.15
mg/kg/dose (range 1-1.4 mg/kg/dose) compared to 0.92mg/kg/dose
(range 0.69-1.3 mg/kg/dose) in the less than 1 year group (p5 0.01).
Engraftment and toxicities were also evaluated in this patient popu-
lation. Veno-occlusive disease was diagnosed in two patients (33.3%)
in the less than 1 year group and no cases were reported in the 1-4
year group. Engraftment was delayed in the 1-4 year group at 25
days compared to 16 days in the less than 1 year group (p 5 0.01).
Graft failure occurred in one patient (10%) in the 1-4 year group.
Conclusions: Patients less than 1 year of age required significantly
lower cumulative busulfan doses to maintain therapeutic levels com-
pared to patients in the 1-4 year age group. Strategies to optimize the
dosing of busulfan in patients less than 1 year of age warrant further
investigation.102
RETROSPECTIVE ANALYSIS OF EFFECTIVENESS OF VENO-OCCLUSIVE
PROPHYLAXIS GUIDELINES IMPLEMENTED FOR PATIENTS RECEIVING
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Hepatic veno-occlusive disease (VOD) is a major and potentially
fatal complication of hematopoietic stem cell transplantation
(HSCT). A risk-adapted VOD prophylaxis guideline was imple-
mented in May 2008 for patients undergoing allogeneic HSCT in
Singapore General Hospital. Patients were stratified into 3 risk cat-
egories according to conditioning regimen and risk factors including
preexisting hepatitis/cirrhosis or hepatic dysfunction. Low risk pa-
tients did not receive routine VODprophylaxis, and patients at mod-
erate or high risk received ursodeoxycholic acid before conditioning
to D+21 of HSCT.Objective:This study evaluated the effectiveness of the guideline as
a tool to identify the need for routine VOD prophylaxis in patients
undergoing allogeneic HSCT. The efficacy of ursodeoxycholic
acid and risk factors associated with VOD development were also
studied.
Method:A retrospective study of patients who underwent allogeneic
HSCT between Jan 2005 and Sept 2010 was carried out where med-
ical records were reviewed. Outcomes were compared between study
group (after guidelines implementation from May 2008 to Sept
2010) and controls (before implementation of guidelines from Jan
2005 – Apr 2008). The primary outcome was the incidence of
VOD; and secondary outcome was VOD-related mortality.
Results: A total of 176 patients were included. The incidence of
VOD was 14.6% in the study group and 20% in controls (p 5
0.42). VOD did not occur in any low risk patients. In the moderate
risk category, a 10.3% reduction in VOD occurrence was associated
with routine prophylaxis (13.9% vs 24.2%). However, this difference
did not reach statistical significance (p5 0.127). Among high risk pa-
tients, the incidence was 36% in the study group and 10% in con-
trols, p 5 0.157. All except for 2 cases of VOD occurred within 21
days after HSCT. Mortality related to VOD did not differ between
the study and control group (3.1% vs. 1.3%, p 5 0.652). Prior
HSCT was identified as risk factor associated with VOD: OR,
4.44; 95% CI, 1.5-13.1; p 5 0.007.
Conclusion: The risk-adapted strategy may be effective in identify-
ing patients who may require routine VOD prophylaxis. The use of
ursodeoxycholic acid as prophylaxis resulted in a non-significant re-
duction inVODoccurrence especially inmoderate risk patients. The
high incidence of VOD among high risk patients underscores the
need for more effective prophylactic strategies. Prior HSCT should
be considered as a risk factor for future patients.103
RELATIONSHIP BETWEEN CLEARANCE OF INTRAVENOUS CALCINEURIN
INHIBITORS AND AREA UNDER THE CONCENTRATION-TIME CURVE
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Background:Oral doses of cyclosporine (CSP) and tacrolimus (TAC)
are conventionally set by multiplying the doses for continuous intrave-
nous infusion by 2 and 4 respectively. It is ideal for the area under the
concentration-time curve (AUC) during oral administration (AUCpo)
to be equal to the AUC during intravenous infusion (AUCiv). In daily
clinical settings, however, we often encounter cases in which changes
in blood concentrations of these drugs deviate from expected values.
Objectives:To assess the appropriateness of conversion ratios of 1:2
for CSP and 1:4 for TAC during the switch from continuous intra-
venous infusion to oral administration by estimating rates of variabil-
ity in AUC, and to investigate factors affecting these AUC changes.
Methods: We studied patients receiving CSP or TAC who under-
went hematopoietic stem cell transplantation between April 2004
and March 2007. There were 37 patients in the CSP, and 69 in the
TAC group. First, the AUCpo/AUCiv ratio was calculated. The
AUCpo was estimated from trough concentrations using a method
described by Nakamura et al (Transplant Proc 2005; 37: 1725).
Next, the patients in each group were divided into 3 subgroups based
on AUCpo/AUCiv ratios: # 4/5; . 4/5 and\ 4/3; $ 4/3, and then
factors associated with AUC changes were investigated.
Results:Themedian value (interquartile range) of AUCpo/AUCiv in
the CSP group was 1.10 (0.79-1.39) while that in the TAC group was
0.82 (0.61-1.05). Patients who reached optimal AUCpo/AUCiv (. 4/
5 and\4/3) were 43% in theCSP group and 38% in theTACgroup.
In the CSP group, comparisons among the 3 subgroups revealed sig-
nificant differences in clearance of intravenous CSP (CLCSP) (P 5
0.019). Multivariate analysis showed that CLCSP $ 0.20 L/hr/kg
was independently associated with AUC decreases (P 5 0.027,
odds ratio 5 7.77). Similarly, in the TAC group, CL of intravenous
TAC (CLTAC) differed significantly among the 3 subgroups (P 5
0.006). Multivariate analysis in the TAC group also showed that
